期刊文献+

3-T MR扩散加权成像诊断前列腺癌最优b值探究 被引量:9

Investigation of the optimal b value in diffusion weighted MR imaging for diagnosis of prostate cancer at 3-T
在线阅读 下载PDF
导出
摘要 目的以磁共振超声融合靶向穿刺联合系统穿刺病理结果为金标准,探究3-T MR扩散加权成像(DWI)诊断前列腺癌的最优b值。方法前瞻性招募临床拟诊为前列腺癌的患者43例,于穿刺前行包括常规T2WI及10个b值(0、50、100、150、200、500、800、1 000、1 500、2 000s/mm2)DWI在内的MR检查。采用DWI联合T2WI对病灶进行分析判断,根据MR诊断结果选择穿刺方式。MR提示有可疑病灶者行靶向穿刺联合系统穿刺,未提示可疑灶者行单纯系统穿刺。选择病理确诊为前列腺癌的患者,测量不同b值病灶及正常组织的DWI信号强度。采用Wilcoxon Signed Ranks非参数配对检验分析不同b值病灶和正常组织信号强度差异是否具有统计学意义,采用受试者工作特征(ROC)曲线计算各b值诊断曲线下面积(AUC)、敏感性和特异性。结果入组病例共43例,22例确诊为前列腺癌,16例为良性前列腺增生,5例为前列腺炎。在确诊为前列腺癌的22例中,16例病灶在b值为1 500s/mm2 DWI上显示较为清晰,6例病灶在b值为2 000s/mm2 DWI上显示较为清晰。Wilcoxon Signed Ranks结果显示当b值为500s/mm2时病灶和正常组织信号强度差异无统计学意义(P=0.236),在其他b值图像上病灶和正常组织信号强度差异均有统计学意义(P<0.000 1)。ROC曲线分析提示b值为1 500s/mm2时AUC最大(0.933)。当诊断的信号强度cut-off值为49.2时,诊断的敏感性和特异性分别为0.909和0.909。结论3-T MR DWI在b值为1 500s/mm2时具有最佳显示病灶能力,在b值为500s/mm2时无法区分诊断前列腺癌与正常组织。 Objective To investigate the optimal b value in diffusion weighted MR imaging for diagnosis of prostate cancer at 3-T while using magnetic resonance/transrectal ultrasound(MR/TRUS)fusion-guided biopsy and system biopsy pathological findings as reference standard.Methods Forty-three consecutive patients were enrolled in this prospective study;they were suspected to have prostate cancer and underwent T2 WI and diffusion-weighted MRI with 10b-values(0,50,100,150,200,500,800,1 000,1 500,and 2 000s/mm^2)prior to biopsy.DWI combined with T2 WI analysis was used for detecting prostate cancer.The biopsy modality was decided by the MRI results:patients had suspicious lesions took MR/TRUS fusionguided biopsy and system biopsy and those had no suspicious lesions took system biopsy only.The signal intensity of prostate cancer lesions and normal prostate tissue on DWI of different b values were measured.Statistical analyses were performed by a Wilcoxon Signed Ranks test to compare the signal intensities between prostate cancer and normal prostate tissue.Receiver operating characteristics(ROC)were used to calculate the AUC,sensitivity,and specificity,so as to determine the optimal b value for revealing prostate cancer on DWI.Results Twenty-two of the 43 patients were diagnosed as prostate cancer,with 16 diagnosed as benign prostate hyperplasia(BPH)and 5as prostatitis.Among the 22 prostate cancer patients b=1 500s/mm^2 and b=2 000s/mm^2 DWI images provided the best lesion visibility in 16/22 and in 6/22 patients,respectively.Wilcoxon Signed Ranks test showed that the signal intensities of the lesions and the normal tissues were significantly different(P〈0.000 1)at all b values but when at 500s/mm^2(P=0.236).ROC curve indicated that the optimal signal intensity contrast was obtained at b=1 500s/mm^2(P〈0.000 1,AUC=0.933),and the signal intensity cut-off value was 49.2,with the sensitivity and specificity being 0.909 and 0.909,respectively.Conclusion A b value of 1 500s/mm^2 is optimal for 3-T DWI to visualize prostate cancer lesions,and b=500s/mm^2 has the lowest diagnosis efficiency.
出处 《第二军医大学学报》 CAS CSCD 北大核心 2015年第4期402-406,共5页 Academic Journal of Second Military Medical University
基金 上海市卫生和计划生育委员会项目(M20140149)~~
关键词 前列腺肿瘤 鉴别诊断 磁共振成像 扩散加权成像 信号强度 prostatic neoplasms differential diagnosis magnetic resonance imaging diffusion weighted imaging signal intensity
  • 相关文献

参考文献14

  • 1Le J D,Tan N,Shkolyar E,Lu D Y,Kwan L,Marks L S,et al.Multifocality and prostate cancer detection by multiparametric magnetic resonance imaging: correlation with whole-mount histopathology[J].Eur Urol,2015,67: 569-576.
  • 2Hambrock T,Somford D M,Huisman H J,van Oort I M,Witjes J A,Hulsbergen-van de Kaa C A,et al.Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer[J].Radiology,2011,259:453-461.
  • 3Kim C K,Park S Y,Park J J,Park B K.Diffusion-weighted MRI as a predictor of extracapsular extension in prostate cancer [J].AJR Am J Roentgenol,2014,202:W270-W276.
  • 4Soylu F N,Peng Y,Jiang Y,Wang S,Schmid-Tannwald C,Sethi I,et al.Seminal vesicle invasion in prostate cancer: evaluation by using multiparametric endorectal MR imaging [J].Radiology,2013,267:797-806.
  • 5Radtke J P,Kuru T H,Boxler S,Alt C D,Popeneciu I V,Huettenbrink C,et al.Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance[J].J Urol,2015,193:87-94.
  • 6Kim A Y,Kim C K,Park S Y,Park B K.Diffusion-weighted imaging to evaluate for changes from androgen deprivation therapy in prostate cancer [J].AJR Am J Roentgenol,2014,203:W645-W650.
  • 7Decker G,Mürtz P,Gieseke J,Tr?ber F,Block W,Sprinkart A M,et al.Intensity-modulated radiotherapy of the prostate: dynamic ADC monitoring by DWI at 3.0 T[J].Radiother Oncol,2014,113:115-120.
  • 8Zelhof B,Pickles M,Liney G,Gibbs P,Rodrigues G,Kraus S,et al.Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer [J].BJU Int,2009,103:883-888.
  • 9Lang P,Wendland M F,Saeed M,Gindele A,Rosenau W,Mathur A,et al.Osteogenic sarcoma: noninvasive in vivo assessment of tumor necrosis with diffusion-weighted MR imaging[J].Radiology,1998,206:227-235.
  • 10Jie C,Rongbo L,Ping T.The value of diffusion-weighted imaging in the detection of prostate cancer: a meta-analysis [J].Eur Radiol,2014,24:1929-1941.

同被引文献102

  • 1张洪涛,俞鸿凯,郭勃毅,王海屹,白旭,叶慧义.不同b值的表观弥散系数值对前列腺癌分期分级的诊断价值[J].微创泌尿外科杂志,2021(1):55-60. 被引量:6
  • 2黎勇林,唐正严,齐琳,陈志,李东杰,曾铭强,薛睿智,彭川.前列腺癌穿刺活组织检查阳性率影响因素的分析及前列腺癌预测模型的建立[J].中南大学学报(医学版),2015,40(6):651-656. 被引量:8
  • 3刘玉品,杨小庆.肝占位病变扩散加权成像的图像质量评价[J].实用放射学杂志,2006,22(8):962-966. 被引量:15
  • 4张晓鹏,唐磊,孙应实,李洁,曹崑.胃癌MR扩散加权成像扩散敏感因子的选择及其与常规序列的对照研究[J].中华放射学杂志,2007,41(12):1339-1343. 被引量:25
  • 5中华医学会消化内镜学分会,中国抗癌协会肿瘤内镜专业委员会.中国早期食管癌筛查及内镜诊治专家共识意见.胃肠病学2015;04:220-240.
  • 6Heidenreich A,Bastian PJ,Bellmunt J,et al. EAU guide- lines on prostate cancer. Part H :treatment of advanced, relapsing,and castration-resistant prostate cancer [j]. Eu- ropean Urology, 2014,65 (2) : 467-479.
  • 7Godtman RA, Holmberg E, Lilja H, et al. Opportunistic testing versus organized prostate-specific antigen screen- ing:outcome after 18 years in the G~teborg randomized population-based prostate cancer screening trial [J]. Euro- pean Urology, 2015,68 (3) : 354-360.
  • 8Allott EH, Masko EM, Freedland SJ. Obesity and prostate cancer:weighing the evidence [J]. European Urology,2013, 63 (5) : 800-809.
  • 9Knipe DW, Evans DM, Kemp JP, et al. Genetic variation in prostate-specific antigen-detected prostate cancer and the effect of control selection on genetic association stud- ies [J]. Cancer Epidemiology Biomarkers & Prevention, 2014,23(7) : 1356-1365.
  • 10Tewari A, Sooriakumaran P, Bloch DA, et al. Positive surgical margin and perioperative complication rates of primary surgical treatments for prostate cancer: a system- atic review and meta-analysis comparing retropubic,la- paroscopic,and robotic prostatectomy [J]. European Urology, 2012, 62(1):1-15.

引证文献9

二级引证文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部